NO984757L - Gliacellelinjeavledet, neurotropisk faktorreseptor - Google Patents

Gliacellelinjeavledet, neurotropisk faktorreseptor

Info

Publication number
NO984757L
NO984757L NO984757A NO984757A NO984757L NO 984757 L NO984757 L NO 984757L NO 984757 A NO984757 A NO 984757A NO 984757 A NO984757 A NO 984757A NO 984757 L NO984757 L NO 984757L
Authority
NO
Norway
Prior art keywords
gdnf
gdnfr
receptor
nervous system
present
Prior art date
Application number
NO984757A
Other languages
English (en)
Norwegian (no)
Other versions
NO984757D0 (no
Inventor
Gary M Fox
Shuqian Jing
Duanzhi Wen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO984757D0 publication Critical patent/NO984757D0/no
Publication of NO984757L publication Critical patent/NO984757L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
NO984757A 1996-04-22 1998-10-12 Gliacellelinjeavledet, neurotropisk faktorreseptor NO984757L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1590796P 1996-04-22 1996-04-22
US1722196P 1996-05-09 1996-05-09
US08/837,199 US6455277B1 (en) 1996-04-22 1997-04-14 Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides
PCT/US1997/006281 WO1997040152A1 (en) 1996-04-22 1997-04-15 Glial cell line-derived neurotrophic factor receptor

Publications (2)

Publication Number Publication Date
NO984757D0 NO984757D0 (no) 1998-10-12
NO984757L true NO984757L (no) 1998-12-21

Family

ID=27360445

Family Applications (1)

Application Number Title Priority Date Filing Date
NO984757A NO984757L (no) 1996-04-22 1998-10-12 Gliacellelinjeavledet, neurotropisk faktorreseptor

Country Status (19)

Country Link
US (3) US6455277B1 (cs)
EP (1) EP0909316B1 (cs)
JP (1) JP2000509271A (cs)
KR (1) KR20000010571A (cs)
CN (1) CN1219967A (cs)
AT (1) ATE338115T1 (cs)
AU (1) AU720092B2 (cs)
BR (1) BR9708959A (cs)
CA (1) CA2250704C (cs)
CZ (1) CZ324598A3 (cs)
DE (1) DE69736597T2 (cs)
EA (1) EA002924B1 (cs)
ES (1) ES2271968T3 (cs)
HU (1) HUP9902640A3 (cs)
IL (1) IL126553A0 (cs)
NO (1) NO984757L (cs)
NZ (1) NZ332256A (cs)
SK (1) SK140398A3 (cs)
WO (1) WO1997040152A1 (cs)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696259B1 (en) * 1995-11-13 2004-02-24 Licentia Ltd. Assays using glial cell line-derived neurotrophic factor receptors
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
CN1163509C (zh) * 1996-05-08 2004-08-25 拜奥根有限公司 刺激神经和肾生长的RET配体(RetL)
US20020068361A1 (en) * 1997-04-08 2002-06-06 Douglas Clary Methods of evaluating specific cellular functions of receptor protein tyrosine kinases in a ligand independent manner
WO1998054213A2 (en) * 1997-05-30 1998-12-03 Amgen Inc. Neurotrophic factor receptors
US20010003580A1 (en) * 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
DE19816186A1 (de) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
FI20000394A0 (fi) * 2000-02-21 2000-02-21 Airaksinen Matti GFRa4:n sukuisia tai siitä johdettuja aineita sekä niiden käyttö
CA2519227C (en) 2003-03-19 2013-12-03 Biogen Idec Ma Inc. Nogo receptor binding protein
CN1897977A (zh) * 2003-10-20 2007-01-17 Ns基因公司 帕金森氏病的体内基因治疗
US8486893B2 (en) 2004-06-24 2013-07-16 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
CA2583308C (en) * 2004-10-08 2020-01-07 Georgia Tech Research Corporation Microencapsulation of cells in hydrogels using electrostatic potentials
HRP20131066T1 (hr) 2005-07-08 2013-12-06 Biogen Idec Ma Inc. Sp35 antitijela i njihova upotreba
WO2007056161A1 (en) * 2005-11-04 2007-05-18 Biogen Idec Ma Inc. Methods for promoting neurite outgrowth and survival of dopaminergic neurons
CA2729961C (en) 2008-07-09 2018-05-01 Biogen Idec Ma Inc. Li113, li62 variant co2, anti-lingo antibodies
KR102142161B1 (ko) 2012-05-14 2020-08-06 바이오젠 엠에이 인코포레이티드 운동 뉴런 관련 병태 치료용 lingo-2 길항제
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
WO2018089702A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Gdnf fusion polypeptides and methods of use thereof
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
RU2690498C1 (ru) * 2018-05-17 2019-06-04 Федеральное государственное бюджетное научное учреждение "Медико-генетический научный центр" Способ получения ноотропной композиции на основе полипептидных комплексов, выделенных из нейронов и глиальных клеток, полученных методом направленной дифференцировки индуцированных плюрипотентных стволовых клеток человека
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
RU2752906C2 (ru) * 2019-12-26 2021-08-11 Федеральное государственное бюджетное научное учреждение "Медико-генетический научный центр имени академика Н.П. Бочкова" Ноотропная композиция на основе полипептидных комплексов, выделенных из нейрональных прогениторных клеток в условиях теплового шока, и способ ее получения
RU2732600C1 (ru) * 2019-12-26 2020-09-21 Федеральное государственное бюджетное научное учреждение "Медико-генетический научный центр имени академика Н.П. Бочкова" Ноотропная композиция на основе полипептидных комплексов, выделенных из нейрональных прогениторных клеток в условиях гипоксии, и способ ее получения
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
JP2877509B2 (ja) 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
AU679167B2 (en) 1991-09-20 1997-06-26 Amgen, Inc. Glial derived neurotrophic factor
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods

Also Published As

Publication number Publication date
CZ324598A3 (cs) 1999-01-13
KR20000010571A (ko) 2000-02-15
DE69736597D1 (de) 2006-10-12
EP0909316B1 (en) 2006-08-30
HUP9902640A3 (en) 2001-11-28
US20060166325A1 (en) 2006-07-27
NO984757D0 (no) 1998-10-12
IL126553A0 (en) 1999-08-17
WO1997040152A1 (en) 1997-10-30
ATE338115T1 (de) 2006-09-15
NZ332256A (en) 2000-03-27
EA199800933A1 (ru) 1999-04-29
US6455277B1 (en) 2002-09-24
EP0909316A1 (en) 1999-04-21
SK140398A3 (en) 1999-04-13
CN1219967A (zh) 1999-06-16
US20030175876A1 (en) 2003-09-18
AU720092B2 (en) 2000-05-25
ES2271968T3 (es) 2007-04-16
DE69736597T2 (de) 2006-12-21
HUP9902640A2 (hu) 1999-11-29
EA002924B1 (ru) 2002-10-31
BR9708959A (pt) 1999-08-03
CA2250704C (en) 2005-04-12
CA2250704A1 (en) 1997-10-30
JP2000509271A (ja) 2000-07-25
AU2730997A (en) 1997-11-12

Similar Documents

Publication Publication Date Title
NO984757L (no) Gliacellelinjeavledet, neurotropisk faktorreseptor
Borasio et al. Involvement of ras p21 in neurotrophin-induced response of sensory, but not sympathetic neurons.
Yap et al. Adaptor protein complex-4 (AP-4) is expressed in the central nervous system neurons and interacts with glutamate receptor δ2
Borroto-Escuela et al. Evidence for the existence of FGFR1–5-HT1A heteroreceptor complexes in the midbrain raphe 5-HT system
CA3081446A1 (en) Methods and compositions for polypeptide analysis
Baron et al. VAPB/ALS8 interacts with FFAT-like proteins including the p97 cofactor FAF1 and the ASNA1 ATPase
EP4071178A1 (en) Method for producing peptide having physiological activity, and peptide comprising short linker
Thompson et al. Overexpression of the GABAA receptor ε subunit results in insensitivity to anaesthetics
US20240110177A1 (en) A screening platform for adar-recruiting guide rnas
Pandey Small peptide recognition sequence for intracellular sorting
Urfer et al. Specificity determinants in neurotrophin-3 and design of nerve growth factor-based trkC agonists by changing central β-strand bundle residues to their neurotrophin-3 analogs
WO1998054213A3 (en) Neurotrophic factor receptors
CA2414355A1 (fr) Peptides lineaires amphipathiques et les compositions les contenant
Rösch et al. The topogenic contribution of uncharged amino acids on signal sequence orientation in the endoplasmic reticulum
Murcia‐Belmonte et al. Biochemical dissection of Anosmin‐1 interaction with FGFR1 and components of the extracellular matrix
Rienzo et al. Perturbation of critical prolines in Gloeobacter violaceus ligand-gated ion channel (GLIC) supports conserved gating motions among Cys-loop receptors
WO1998054213B1 (en) Neurotrophic factor receptors
Park et al. Temporal and spatial expression of neurotrophins and their receptors during male germ cell development
Tetenborg et al. Regulation of Cx36 trafficking through the early secretory pathway by COPII cargo receptors and Grasp55
JPH08511949A (ja) Ｄ４ドーパミン受容体についての合成遺伝子
WO2023159105A1 (en) Phage display-based cell-penetrating peptide discovery platform and methods of making and using the same
Einarsen et al. Functional properties of human neuronal Kv11 channels
Mizuno et al. Localization of molecules involved in cytokine receptor signaling in the rat trigeminal ganglion
EP4735893A1 (en) Targeted proteomics for monitoring autophagy
Sha et al. Receptor-Bound Conformation of α-Peptide of Transducin (Gt) is not Stabilized by a “π-Cation” Interaction but by Constrained Lactam Bridges Between Residues 341 and 350

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application